NOD2, CD14 and TLR4 mutations do not influence response to adalimumab in patients with Crohn's disease: a preliminary report Las mutaciones de NOD2, CD14 y TLR4 no influyen sobre la respuesta al adalimumab en pacientes con enfermedad de Crohn: informe preliminar

NOD2, CD14 and TLR4 mutations do not influence response to adalimumab in patients with Crohn's disease: a preliminary report Las mutaciones de NOD2, CD14 y TLR4 no influyen sobre la respuesta al adalimumab en pacientes con enfermedad de Crohn: informe preliminar

Introduction: adalimumab is a recombinant fully-human monoclonal immunoglobulin (IgG1) antibody utilized in the treatment of Crohn's disease. Unfortunately no clinical or genetic markers exist to predict response to anti-tumor necrosis factor-alpha (TNF) therapy. The aim of this study was to ev...

Full description

Bibliographic Details
Main Authors:	M. Barreiro-de Acosta, S. Ouburg, S. A. Morré, J. B. A. Crusius, A. Lorenzo, J. Potel, A. S. Peña, J. E. Domínguez-Muñoz
Format:	Article
Language:	English
Published:	Aran Ediciones 2010-10-01
Series:	Revista Espanola de Enfermedades Digestivas
Subjects:	Crohn's disease Genotypes Adalimumab
Online Access:	http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1130-01082010001000005

Similar Items

Adalimumab and azathioprine in the prevention of postoperative crohn’s disease recurrence
by: A. V. Poletova, et al.
Published: (2020-10-01)

CROHN'S DISEASE: GENERAL CHARACTERISTICS AND TREATMENT WITH ADALIMUMABE BIOPHARMACEUTICAL
by: S. A. Marques, et al.
Published: (2018-02-01)

Crohn's Disease: General characteristics and treatment with Adalimumabe biopharmaceutical
by: S. A. Marques, et al.
Published: (2018-02-01)

Leukocytoclastic Vasculitis Associated with Adalimumab Therapy for Crohn’s Disease
by: Lankai Cathy Xu, et al.
Published: (2023-03-01)

Crohn’s Disease Associated Pyoderma Gangrenosum Treated with Adalimumab
by: Despoina Kakagia, et al.
Published: (2012-03-01)

Efficacy and safety of adalimumab in the treatment of Crohn's disease in children
by: Víctor Manuel Navas-López, et al.
Published: (2013-12-01)

Efficacy of adalimumab for the treatment of extraintestinal manifestations of Crohn's disease Eficacia del adalimumab en el tratamiento de las manifestaciones extraintestinales de la enfermedad de Crohn
by: Manuel Barreiro-de-Acosta, et al.
Published: (2012-09-01)

Listeria Monocytogenes Brain Abscess in Crohn’s Disease Treated with Adalimumab
by: Amporn Atsawarungruangkit, et al.
Published: (2017-11-01)

Efficacy of adalimumab for Crohn’s disease in real clinical practice
by: O V Knyazev, et al.
Published: (2017-02-01)

Langerhans Cell Histiocytosis Caused by Adalimumab for Crohn’s Disease: A Case Report
by: Mariko Kochi, et al.
Published: (2023-06-01)

Adherence to and Persistence with Adalimumab Therapy among Swedish Patients with Crohn’s Disease
by: Yifei Liu, et al.
Published: (2022-07-01)

Distinct alterations of fecal microbiota refer to the efficacy of adalimumab in Crohn’s disease
by: Liang Chen, et al.
Published: (2022-08-01)

Treatment persistence during therapeutic sequences with adalimumab and infliximab in the treatment of Crohn's disease
by: Carlos Taxonera, et al.

Adalimumab Dose-Escalation Therapy Is Effective in Refractory Crohn’s Disease Patients with Loss of Response to Adalimumab, Especially in Cases without Previous Infliximab Treatment
by: Taketo Suzuki, et al.
Published: (2019-02-01)

Tratamiento de inducción y mantenimiento con adalimumab en la enfermedad de Crohn: un estudio abierto Adalimumab induction and maintenance therapy from Crohn's diseas: An open-label study
by: N. López Palacios, et al.
Published: (2008-11-01)

Adalimumab
by: Nilgun Atakan
Published: (2022-04-01)

HEPATITIS AND PNEUMONITIS DURIN ADALIMUMAB THERAPY IN CROHN? DISEASE: mind the histoplasmosis!
by: Bruno do Valle PINHEIRO, et al.
Published: (2014-03-01)

Long-Term Clinical Remission in Biologically Naïve Crohn’s Disease Patients with Adalimumab Therapy, Including Analyses of Switch from Adalimumab to Infliximab
by: Tsutomu Mizoshita, et al.
Published: (2016-06-01)

Adalimumab induction and maintenance therapy achieve clinical remission and response in Chinese patients with Crohn's disease
by: Kai-Chun Wu, et al.
Published: (2016-04-01)

Efficacy of adalimumab in patients with crohn's disease and failure to infliximab therapy: a clinical series Eficacia de Adalimumab en pacientes con enfermedad de Crohn y fracaso previo a la terapia con Infliximab: resultados de una serie clínica
by: Patricia Cordero-Ruiz, et al.
Published: (2011-06-01)

Isolated Bilateral Gastrocnemius Myositis in Crohn Disease Successfully Treated with Adalimumab
by: Salvatore Vadala di Prampero, et al.
Published: (2016-11-01)

Adalimumab for induction of remission in patients with Crohn's disease: a systematic review and meta-analysis
by: Juntao Yin, et al.
Published: (2022-09-01)

Crohn's-like disease in a patient with common variable immunodeficiency treated with azathioprine and adalimumab
by: Juan María Vázquez-Morón, et al.
Published: (2013-06-01)

Administration Timing Is the Best Clinical Outcome Predictor for Adalimumab Administration in Crohn's Disease
by: Mauro Mastronardi, et al.
Published: (2019-11-01)

Hidradenitis Suppurativa as a Paradoxical Side Effect to the Use of Adalimumab in Patients with Crohn’s Disease?
by: Beraldo RF, et al.
Published: (2020-08-01)

Outcomes of limited period of adalimumab treatment in moderate to severe Crohn's disease patients: Taiwan Society of Inflammatory Bowel Disease Study
by: Wei-Chen Lin, et al.
Published: (2017-10-01)

Vitiligo during Treatment of Crohn’s Disease with Adalimumab: Adverse Effect or Co-Occurrence
by: Celia Posada, et al.
Published: (2011-02-01)

ADALIMUMAB INDUCTION AND MAINTAINING REMISSION FOR CROHN’S DISEASE IN PATIENT WHO LOST RESPONSE TO INFLIXIMAB. Case report
by: Ivaylo Vazharov, et al.
Published: (2016-12-01)

Determination of lower cut‐off levels of adalimumab associated with biochemical remission in Crohn's disease
by: Arne Carlsen, et al.
Published: (2020-06-01)

Safety and Efficacy of Adalimumab for Patients With Moderate to Severe Crohn's Disease: The Taiwan Society of Inflammatory Bowel Disease (TSIBD) Study
by: Chen-Wang Chang, et al.
Published: (2014-10-01)

Adalimumab versus infliximab in treating post-operative recurrence of Crohn's disease: a national cohort study
by: Carmen-Monica Preda, et al.

Clinical efficacy of adalimumab versus infliximab and the factors associated with recurrence or aggravation during treatment of anal fistulas in Crohn's disease
by: Cheng-Chun Ji, et al.
Published: (2017-04-01)

Diffuse large B-cell lymphoma that develops after adalimumab using adalimumab in a patient with psoriasis
by: Esra Yıldırım Bay, et al.
Published: (2021-06-01)

Unilateral Verrucous Psoriasis Successfully Treated With Adalimumab
by: Artur Antônio Duarte, et al.
Published: (2024-01-01)

Clinical status, quality of life, and work productivity in Crohn's disease patients after one year of treatment with adalimumab
by: Cristina Saro, et al.

Criptosporidiose em paciente com espondilite anquilosante usando adalimumabe Cryptosporidiosis in a patient with ankylosing spondylitis treated with adalimumab
by: Fernando Augusto Chiuchetta
Published: (2010-06-01)

MIF Variant rs755622 Is Associated with Severe Crohn’s Disease and Better Response to Anti-TNF Adalimumab Therapy
by: Gregor Jezernik, et al.
Published: (2023-02-01)

A Case of Lip Psoriasis in a 14-Year-Old Boy Successfully Treated with Adalimumab
by: Francesca Caroppo, et al.
Published: (2023-09-01)

Association of NOD2/CARD15 mutations with previous surgical procedures in Crohn's disease Asociación entre las mutaciones del gen NOD2/CARD15 con los antecedentes quirúrgicos por enfermedad de Crohn
by: M. Barreiro, et al.
Published: (2005-08-01)

Treatment of granulomatous rosacea with adalimumab
by: Ryan C. Saal, BS, et al.
Published: (2023-10-01)